Published date: Dec 31 2022

Journal Title: Sudan Journal of Medical Sciences

Issue title: Sudan JMS: Volume 17 (2022), Issue No. 4

Pages: 476–484

DOI: 10.18502/sjms.v17i4.12548

Osman Elsayed OsmanDepartment of Medicine, Faculty of Medicine, Al Neelain University, Khartoum, Sudan

Rabeea Ibrahim Haroun IsmailDepartment of Cardiology, Ahmed Gasim Specialized Hospital, Khartoum, Sudan

Rayan KhalidDepartment of Physiology, Assafa College, Khartoum, Sudan

Imad Fadl-Elmuladean@assafa.edu.sdDepartment of Clinical Genetics, Assafa College, Khartoum, Sudan

Background: Although warfarin is known as effective oral anticoagulant to prevent thromboembolic events, its’ narrow therapeutic index requires ambient and good follow-up to reduce its therapeutic complications. There is a continuous debate whether the best practice to accomplish this goal is in a specialized international normalized ratio clinic (INR-C) or in a general medical clinic (General-C). Few, if any, studies have been done in Sudan to compare the safety and efficacy of anticoagulant therapy in those clinics. Thus, the objective of this study was to compare the efficacy and safety of anticoagulant therapy in INR-C and in General-C.
Methods: This is a prospective hospital-based study where 200 patients were divided into two groups (group A and B) of 100 patients. Group A were in the INR-C at Ahmed Gasim specialized hospital and group B in the General-Cat AL-Shaab teaching hospital. The study was conducted from September 2019 to April 2020. All patients were on warfarin treatment and regular follow-ups were conducted. Demographic and clinical data were collected and analyzed statistically using SPSS version 20. Ethical approval was obtained from the ethical committee of the Sudanese Medical Specialization Board (SMSB).
Results: Of the 200 patients, 118/59% were females and 82/41% were males. Target international normalized ratio (INR) for group (A) was achieved in 56% of the patients in the first visit, increased to 63% in the second visit, and 75% in the third follow-up, compared with 24% of the patients from group (B) in the initial and second follow-up visit, to 43% in the third visit (P value=0.05). Knowledge about drug and food interaction of coagulation agents was higher (91%) among patients in group (A) compared with group (B) (56%). Drug interaction awareness was found in 89% of the patients in group (A) compared with only 40% in group (B) (P value=0.05). Major bleeding was reported in 2% and 14% of the patients of group (A) and (B) respectively, whereas minor bleeding was seen in 4% of group (A) and 11% of group (B).
Conclusion: The study showed that INR-C is more efficient and safer for patients on regular warfarin therapy compared with the General-C.

Keywords: specialized INR clinic, anticoagulant therapy, warfarin

[1] Robinson, A. A., Trankle, C. R., Eubanks, G., Schumann, C., Thompson, P., Wallace, R. L., Gottiparthi, S., Ruth, B., Kramer, C. M., Salerno, M., Bilchick, K. C., Deen, C., Kontos, M. C., & Dent, J. (2020). Off-label use of direct oral anticoagulants compared with warfarin for left ventricular thrombi. JAMA Cardiology, 5(6), 685– 692. https://doi.org/10.1001/jamacardio.2020.0652

[2] Michaels, K., Regan, E. N. (2013). Teaching patients INR self-management. Nursing2020, 43(5):67–9. https://doi.org/10.1097/01.NURSE.0000428711.89001.61

[3] van Walraven, C., Jennings, A., Oake, N., Fergusson, D., & Forster, A. J. (2006). Effect of study setting on anticoagulation control: A systematic review and metaregression. Chest, 129(5), 1155–1166. https://doi.org/10.1378/chest.129.5.1155

[4] Pell, J. P., & Alcock, J. (1994). Monitoring anticoagulant control in general practice: Comparison of management in areas with and without access to hospital anticoagulant. The British Journal of General Practice, 44(385), 357–358.

[5] Testa, S., Paoletti, O., Zimmermann, A., Bassi, L., Zambelli, S., Cancellieri, E. (2012). The role of anticoagulation clinics in the era of new oral anticoagulants. Thrombosis, 2012, 835356. https://doi.org/10.1155/2012/835356

[6] Morgan, C. L., McEwan, P., Tukiendorf, A., Robinson, P. A., Clemens, A., & Plumb, J. M. (2009). Warfarin treatment in patients with atrial fibrillation: Observing outcomes associated with varying levels of INR control. Thrombosis Research, 124(1), 37–41. https://doi.org/10.1016/j.thromres.2008.09.016

[7] Zhao, S. J., Zhao, H. W., Wang, X. P., Gao, C. Y., Qin, Y. H., Cai, H. X., Chen, B. Y., & Cao, J. J. (2016). [Current status of warfarin therapy in Chinese patients with nonvalvular atrial fibrillation: A single center analysis]. Zhonghua Xin Xue Guan Bing Za Zhi, 44(11), 940–944.

[8] Chiquette, E., Amato, M. G., & Bussey, H. I. (1998). Comparison of an anticoagulation clinic with usual medical care: Anticoagulation control, patient outcomes, and health care costs. Archives of Internal Medicine, 158(15), 1641–1647. https://doi.org/10.1001/archinte.158.15.1641

[9] Lafata, J. E., Martin, S. A., Kaatz, S., & Ward, R. E. (2000). The cost-effectiveness of different management strategies for patients on chronic warfarin therapy. Journal of General Internal Medicine, 15(1), 31–37. https://doi.org/10.1046/j.1525- 1497.2000.01239.x

[10] Brown, D. G., Wilkerson, E. C., & Love, W. E. (2015). A review of traditional and novel oral anticoagulant and antiplatelet therapy for dermatologists and dermatologic surgeons. Journal of the American Academy of Dermatology, 72(3), 524–534. https://doi.org/10.1016/j.jaad.2014.10.027

[11] Alghadeeer, S., Alzahrani, A. A., Alalayet, W. Y., Alkharashi, A. A., & Alarifi, M. N. (2020). Anticoagulation Control of Warfarin in Pharmacist-Led Clinics Versus Physician-Led Clinics: A Prospective Observational Study. Risk Management and Healthcare Policy, 13, 1175–1179. https://doi.org/10.2147/RMHP.S248222

[12] Kuruvilla, M., & Gurk-Turner, C. (2001). A review of warfarin dosing and monitoring. Proceedings - Baylor University. Medical Center, 14(3), 305–306. https://doi.org/10.1080/08998280.2001.11927781

[13] Lee, Y.-P., & Schommer, J. C. (1996). Effect of a pharmacist-managed anticoagulation clinic on warfarin-related hospital readmissions. American Journal of Health-System Pharmacy, 53(13), 1580–1583. https://doi.org/10.1093/ajhp/53.13.1580

[14] Shoeb, M., & Fang, M. C. (2013). Assessing bleeding risk in patients taking anticoagulants. Journal of Thrombosis and Thrombolysis, 35(3), 312–319. https://doi.org/10.1007/s11239-013-0899-7

[15] Camm, A. J., Lip, G. Y., De Caterina, R. (2012). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Europace, 14, 1385–1413.

[16] Al-Momany, N. H., Makahleh, Z. M., Al-Omari, N. A., Al-Sarayreh, H. A., & Momani, R. O. (2019). Analysis of factors that interrupt with INR control in the first anticoagulation clinic monitoring Jordanian patients. Clinical and Applied Thrombosis/Hemostasis, 25, 1076029619870252. https://doi.org/10.1177/1076029619870252

[17] Li, X., Sun, S., Wang, Q., Chen, B., Zhao, Z., & Xu, X. (2018). Assessment of patients’ warfarin knowledge and anticoagulation control at a joint physician- and pharmacist-managed clinic in China. Patient Preference and Adherence, 12, 783– 791. https://doi.org/10.2147/PPA.S156734